How CagriSema works
An unapproved cagrilintide–semaglutide combination with phase 3 weight-loss and diabetes results.
Also called: Cagrilintide/semaglutide, Cagrilintide-semaglutide, CagriSema 2.4 mg/2.4 mg.
Amylin analogues · Combination of an amylin analogue and a GLP-1 receptor agonist.
Cagrilintide signals fullness through amylin pathways. Semaglutide activates GLP-1 receptors, supporting fullness and glucose-dependent insulin release. The two drugs act through complementary pathways; their combination can reduce eating more than either drug alone.
- Amylin and calcitonin-family receptors: Cagrilintide adds fullness signals through brain pathways.
- GLP-1 receptor: Semaglutide supports fullness, insulin release when glucose is high, and slower stomach emptying.
Half-life: Cagrilintide 159–195 hours; semaglutide 145–165 hours in the phase 1b study.
Related to CagriSema
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
- Pramlintide: A diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society., Mozaffarian D et al. · The American journal of clinical nutrition · 2025
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- Chest pain, NHS
- European Medicines Agency decision P/0307/2023 of 4 August 2023 on the granting of a product specific waiver for cagrilintide / semaglutide (EMEA-003059-PIP02-23)
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, US Food and Drug Administration
- PIP Search Page, MHRA
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products
- Vision loss, NHS
- Wegovy PI, Novo Nordisk
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study., Rosenstock J et al. · Lancet (London, England) · 2026
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study., Buse JB et al. · The lancet. Diabetes & endocrinology · 2026
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1., Verma S et al. · Hypertension (Dallas, Tex. : 1979) · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.